Disease relevance of FCN3

• Serum concentration of Hakata antigen, a member of the ficolins, is linked with inhibition of Aerococcus viridans growth [1].
• Purified Hakata antigen sustained lectin activity, showing affinity with GalNAc, GlcNAc, D-fucose as mono/oligosaccharide, and lipopolysaccharides from Salmonella typhimurium and Salmonella minnesota [2].
• Expression of H-ficolin/Hakata antigen, mannose-binding lectin-associated serine protease (MASP)-1 and MASP-3 by human glioma cell line T98G [3].
• Thermolabile beta-2 macroglycoprotein (Hakata antigen) in liver disease: biochemical and immunohistochemical study [4].

High impact information on FCN3

• For comparison, FCN1 and FCN3 were also investigated [5].
• Activation of the lectin complement pathway by H-ficolin (Hakata antigen) [6].
• The Hakata antigen is a novel, thermolabile beta2-macroglycoprotein that reacts with sera from patients suffering from systemic lupus erythematosus [2].
• Out of 17 cell lines tested using RT-PCR, a human glioma cell line, T98G, expressed high levels of H-ficolin/Hakata antigen, MASP1 and MASP3 mRNAs [3].
• In the liver, Hakata antigen was produced by bile duct epithelial cells and hepatocytes and was also secreted into the bile duct [7].

Chemical compound and disease context of FCN3

• Detection of serum thermolabile beta-2 macroglycoprotein (Hakata antigen) by enzyme-linked immunosorbent assay using polysaccharide produced by Aerococcus viridans [8].

Biological context of FCN3

• In this study we analyzed the tissue distribution of Hakata antigen [7].

Anatomical context of FCN3

• In the lung, Hakata antigen was produced by both ciliated bronchial epithelial cells and Type II alveolar epithelial cells and was secreted into the bronchus and alveolus [7].

Other interactions of FCN3

• SDS-PAGE and immunoblotting analyses showed the secreted H-ficolin/Hakata antigen, MASP-1 and MASP-3 to be 34, 81 and 105 kDa in size respectively, similar to their serum counterparts [3].
• A novel thermolabile beta-2 macroglycoprotein ('thermolabile substance' (TLS) or 'Hakata antigen' (HA], which was detected by the precipitating (auto) antibodies of patients with systemic lupus erythematosus, was isolated and characterized [9].

Analytical, diagnostic and therapeutic context of FCN3

• Data from the Ames TA-98 mutagenic bioassay clearly indicate that vai haka is not mutagenic with or without S-9 activation [10].
• Twenty-six experimental CD-1 white mice were gavaged with 0.1 ml of vai haka (at 540xthe human dose) while the control group of 17 mice were gavaged with 0.1 ml of water to determine teratogenic and developmental effects of the vai haka [10].

References